Selects drug candidate & enters next phase of development with TrkA-NAM ACD137 against severe pain скачать в хорошем качестве

Selects drug candidate & enters next phase of development with TrkA-NAM ACD137 against severe pain

AlzeCure has selected a TrkA-NAM drug candidate, ACD137, and started the preclinical development phase with the compound. ACD137 is being developed within the TrkA-NAM project in AlzeCure's Painless platform, with the aim of developing a new pain-relieving drug for the treatment of osteoarthritis and other severe pain conditions. Disclaimer Any content posted on this YouTube channel is made available for informational purposes only. It is not intended to and should not be relied upon or construed as financial advice regarding Alzecure Pharma AB (the “Company”) or any specific product, issue or factual circumstance. We, the Company, do not guarantee the accuracy or completeness of the information contained herein. Furthermore, the information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. Although the Company attempts to provide accurate and up-to-date information, no guarantee is made to that effect. You are solely allowed to access any content posted on this channel as it is presented by us, the Company. Any further use of such content (including but not limited to copying, reproducing, making available, incorporating the content into other works etc.) is subject to our prior written authorization. We, the Company, are not responsible for any third-party comments or other content that is posted, linked to or otherwise made available in relation to this content.